Xyosted Subcutaneous TRT Efficacy and Safety in Phase 3 Trials

Estimated reading time: 8 minutes

Key takeaways

Phase 3 trials (QST‑13‑003, QST‑15‑005) showed a 90% responder rate achieving eugonadal testosterone (Cavg 300–1100 ng/dL) with once‑weekly 50–100 mg dosing and titration [1,3].
Monitoring is essential: expect hematocrit checks and blood pressure tracking; average systolic BP increase of ~4 mmHg was observed on ABPM [1,2,4].
Subcutaneous autoinjector reported low pain with mostly mild local reactions; needle is concealed for at‑home use [2,3].
Indicated for men with classical hypogonadism; not approved for age‑related low testosterone; labeling emphasizes hematocrit and BP monitoring [1,2,4].

What Is Xyosted Testosterone?
The Phase 3 Evidence at a Glance: QST‑13‑003 and QST‑15‑005
Efficacy: 90% Achieved Eugonadal Testosterone Levels
Safety and Monitoring: What to Know
How the Xyosted Autoinjector Compares With Other TRT Methods
Dosing and Titration: What Patients Can Expect
Who Might Consider Xyosted—and Who Should Not
Practical Questions From Patients
What Changed With FDA Approval?
Limitations and Open Questions
Bottom Line

Xyosted Subcutaneous Auto-Injector TRT: Efficacy and Safety from Phase 3 Pivotal Data

Interest in at-home, low-pain testosterone delivery has grown as more men balance symptom relief with practical day-to-day treatment. Xyosted—an FDA‑approved, once‑weekly subcutaneous testosterone enanthate autoinjector—offers a needle-concealed, preset-dose option designed for consistent pharmacokinetics without the gel-to-skin transfer risk. Below, we review what the pivotal Phase 3 studies found about efficacy, safety, and how this route compares with other testosterone replacement therapy (TRT) options.

What Is Xyosted Testosterone?

Xyosted is a subcutaneous (under‑the‑skin) autoinjector that delivers testosterone enanthate once weekly. It is available in preset strengths (50 mg, 75 mg, 100 mg) and is intended for adults with confirmed hypogonadism due to specific medical causes (e.g., primary testicular failure or pituitary‑hypothalamic disorders), not for age-related testosterone decline [4]. The device is designed for at‑home use after appropriate instruction, offering an alternative to intramuscular injections or daily transdermal products [4].

For many patients, the convenience of weekly dosing and the discreet, needle‑concealed applicator are practical advantages. Pharmacokinetically, the subcutaneous route aims to deliver stable exposure, and doses can be adjusted based on testosterone levels measured at the appropriate time points during therapy [1,4].

The Phase 3 Evidence at a Glance: QST‑13‑003 and QST‑15‑005

QST‑13‑003: Open‑label, up to 52 weeks, n=150 hypogonadal men; primary endpoint at Week 12 [1].
QST‑15‑005: 6 months, n=133 hypogonadal men, with additional pharmacokinetic and safety characterization [1,2,3].

Who was studied? Across studies, participants were adult men with classical hypogonadism (mean age around 54; most were under 65) [1].

Study design matters: These were open‑label, single‑arm trials without concurrent control groups. While this design reflects real‑world titration and monitoring, it limits direct comparisons versus other TRT modalities [1].

Efficacy: 90% Achieved Eugonadal Testosterone Levels

In QST‑13‑003, 90% (135/150) of participants reached average serum testosterone (Cavg) between 300 and 1100 ng/dL at Week 12 with weekly dosing (50–100 mg) and a planned titration around Week 7 based on measured levels [1,3].
The 95% confidence interval for the primary endpoint was reported at approximately 84–94.3%, reinforcing a robust response rate under trial conditions [1].
Pharmacokinetic data supported stable weekly exposure following subcutaneous administration, aligning with the intended once‑weekly schedule [1,3].

What this means for patients: For appropriately selected men with confirmed hypogonadism, Xyosted’s dosing strategy achieved target testosterone ranges at rates comparable to established TRT methods—without the burden of intramuscular needles or daily gels.

Safety and Monitoring: What to Know

Xyosted’s safety profile largely mirrors class-wide TRT considerations, with a few route- and product‑specific details emphasized on the label.

Hematocrit: Monitor for Erythrocytosis

Elevations in hematocrit occurred during treatment in the Phase 3 program; this is a known TRT effect and a key reason monitoring is required [1,2,4].
The label instructs clinicians to monitor hematocrit during therapy and to manage elevations according to practice standards, which can include dose adjustments or treatment interruption if values rise excessively [4].

Why it matters: Rising hematocrit can thicken blood and increase thrombotic risk. Practical implication: expect regular blood-work checks; make sure your care team has a plan if hematocrit trends upward.

Blood Pressure: Small Average Increase, Clinical Relevance Varies

In QST‑15‑005, ambulatory blood pressure monitoring indicated an average systolic increase of about 4 mmHg with Xyosted [1,2].
In longer observation (QST‑13‑003), a subset of participants initiated or adjusted antihypertensive therapy during the study [1].
The Prescribing Information highlights blood pressure as a labeled risk, advising assessment and ongoing management during therapy [4].

Practical implication: If you have hypertension or cardiovascular risk factors, discuss how blood pressure will be tracked and managed while on Xyosted.

Prostate and PSA

Modest PSA increases were observed in some participants, consistent with TRT class effects [1,2,4].
Labeling advises baseline evaluation and monitoring in accordance with prostate health guidelines [4].

Practical implication: Expect routine PSA and clinical prostate assessments as part of follow‑up.

Injection‑Site Tolerability

Nearly all injections were rated pain‑free in study reports (≈99%); about 13% had mild injection‑site reactions, with very few discontinuations attributed to local tolerability [2,3].
Subcutaneous delivery avoids intramuscular needles and may be more comfortable for many patients.

Practical implication: Technique training matters—proper site rotation and adherence to instructions can help maintain good tolerability.

Other Common TRT Considerations

Potential adverse effects can include acne or oilier skin, changes in mood or libido, edema, and altered lipids—class-wide considerations that warrant routine monitoring and communication with your clinician [4].
Patients with certain underlying conditions (e.g., severe obstructive sleep apnea, uncontrolled heart failure, or known/suspected prostate or breast cancer) require special consideration or may be unsuitable for TRT as outlined in labeling [4].

How the Xyosted Autoinjector Compares With Other TRT Methods

Administration route and convenience
- Xyosted: subcutaneous, once weekly, preset doses (50/75/100 mg), concealed needle [4].
- Intramuscular injections: vary by ester and regimen (often weekly to biweekly), typically require longer needles; some self‑inject, others visit a clinic.
- Transdermal gels/solutions: daily application; risk of testosterone transfer to others through skin contact; local skin reactions possible.
Pharmacokinetic profile
- Xyosted: aims for stable weekly exposure via subcutaneous depot; titration around early weeks is guided by serum levels [1,4].
- Intramuscular esters: may produce higher peaks and lower troughs between injections depending on dose interval.
- Gels: steady daily exposure, but adherence is day‑to‑day and application technique affects absorption.
Tolerability
- Xyosted: high proportion of pain‑free injections in trials; mild local reactions in a minority [2,3].
- Intramuscular: potential for injection discomfort and post‑injection fluctuations.
- Gels: no needles, but potential for skin irritation and transfer precautions.
Monitoring needs
- All TRT modalities require monitoring of hematocrit, PSA, testosterone levels, and cardiovascular parameters per label and clinical practice standards [4]. Xyosted adds explicit label language around blood pressure.

No single route is “best” for everyone. The right fit depends on your diagnosis, lifestyle, comorbidities, tolerance for different delivery methods, and how your levels respond in practice.

Dosing and Titration: What Patients Can Expect

Xyosted offers preset weekly doses, with a label‑guided titration approach based on serum testosterone levels drawn at specified times after initiation [1,4]. In QST‑13‑003, investigators titrated around Week 7 using a single time‑point level to achieve eugonadal targets by Week 12 [1]. Your clinician will determine when to draw labs and whether to adjust your weekly dose.

Practical implication: Keep your lab appointments aligned with the dosing schedule your provider recommends. A blood draw at the wrong time can mislead titration decisions.

Who Might Consider Xyosted—and Who Should Not

Xyosted is indicated for men with classical hypogonadism confirmed by clinical features and consistently low morning testosterone levels. It is not approved for age‑related testosterone decline without an established pathological cause [4]. Men with significant cardiovascular disease, uncontrolled hypertension, or elevated hematocrit at baseline may need additional evaluation and risk‑benefit discussions before starting any TRT [4].

If fertility is a priority, note that exogenous testosterone can suppress spermatogenesis. Discuss fertility‑sparing options with your clinician before starting TRT [4].

Practical Questions From Patients

Will I feel a peak and crash with weekly subcutaneous dosing?
Phase 3 data support stable weekly exposure with Xyosted’s subcutaneous route, and the responder rate was high after titration [1,3]. Individual experiences vary, and timing of labs can help refine dosing.
Is it really low‑pain?
In trials, nearly all injections were reported as pain‑free, and injection‑site reactions were generally mild [2,3]. Good injection technique helps.
What happens if my hematocrit goes up?
This is a known TRT effect. The label advises monitoring and clinical management, which can include dose changes or pausing therapy if thresholds are exceeded [4].
How does blood pressure factor in?
Expect blood pressure checks during therapy; the average systolic increase observed in study ABPM was around 4 mmHg, but individual responses vary [1,2]. Managing baseline hypertension and lifestyle factors remains important.

For patients working with Taurus Meds, care teams can coordinate lab schedules, help interpret results with your prescribing clinician, and discuss whether a subcutaneous testosterone autoinjector aligns with your goals and medical history.

What Changed With FDA Approval?

Xyosted received FDA approval in 2019 based on the Phase 3 data above. The approval incorporated labeling language addressing blood pressure increases and hematocrit monitoring. FDA documents note no chemistry, manufacturing, or efficacy deficiencies; earlier regulatory concerns were resolved through risk communication and monitoring requirements reflected in the final label [1,2,4].

Limitations and Open Questions

Study design: The pivotal trials were open‑label without concurrent comparisons to other TRT formulations [1].
Duration: Data extend to 6–12 months; many men use TRT long‑term, and real‑world outcomes beyond a year—especially cardiovascular endpoints—warrant ongoing study [1,2].
Comparative effectiveness: Head‑to‑head trials versus intramuscular injections, transdermal gels, or oral formulations would clarify differences in patient‑reported outcomes, adherence, and long‑term safety.
Population: Results are in men with classical hypogonadism; applicability to other groups (e.g., age‑related low T) is not supported by labeling [4].

Bottom Line

For men with confirmed hypogonadism, Xyosted offers a weekly subcutaneous testosterone option that produced a 90% responder rate for eugonadal levels in Phase 3 studies, with a safety profile consistent with TRT class effects. Monitoring hematocrit, blood pressure, PSA, and serum testosterone remains essential. The autoinjector’s ease of use, low reported injection pain, and steady exposure profile make it a compelling alternative to intramuscular injections or daily gels for the right patient—provided it is chosen within a structured, monitored care plan.

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice. Do not start, stop, or change any medication without guidance from a qualified healthcare provider. Xyosted is indicated only for men with confirmed hypogonadism due to certain medical causes, not for age‑related low testosterone.

Xyosted Subcutaneous TRT Efficacy and Safety in Phase 3 Trials